Brainstorm Cell Therapeutics Inc.

OTC: BCLI · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001137883Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 6DQ —GM —SS 55

v0.1 · 35/100 weight · pillars only

↑ listing tenure, market scale · ↓ Piotroski F, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$10.3M

Employees

as of 2026-08-21

Market cap

$11.7M

as of 2026-08-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$10.3M-$10.3M2025

Operating income-$10.0M-$10.0M2025

Total assets$1.0M$1.0M2025

Liabilities$11.0M$11.0M2025

Equity-$10.0M-$10.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Brainstorm Cell Therapeutics Inc.’s financial profile?

Brainstorm Cell Therapeutics Inc. earned -$10.3M in FY2025 net income.

Peers · Healthcare

Anebulo Pharmaceuticals, Inc.——Intensity Therapeutics, Inc.——IN8bio, Inc.——Jasper Therapeutics, Inc.——PDS Biotechnology Corporation——Conavi Medical Corp.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOChaim Lebovits

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeOTC: BCLI

Employees20

IPO date2003-10-07

Latest filings

8-K2026-08-14 10-Q2026-08-14 8-K2026-07-30 8-K2026-05-28 10-Q2026-05-15 8-K2026-05-15 10-K2026-03-31 8-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.